Nafta I, TTurcanu A G, Braun I, Companetz W, Simionescu A, Birţ E, Florea V
Bull World Health Organ. 1970;42(3):423-7.
The prophylactic effectiveness of amantadine against A2/Hong Kong influenza was investigated in the course of a double-blind trial in Braşov, Romania, during an epidemic due to the Hong Kong virus that started there in March 1969.Altogether 215 subjects were included in the trial; 112 received 100 mg of amantadine twice daily for 20 days and the remaining 103 received inert placebo tablets. Of the amantadine-treated group, 2 had clinical symptoms diagnosed as influenza (1 of these was a doubtful diagnosis), whereas 20 (1 doubtful) of the placebo group had such symptoms. No case with both clinical symptoms and serologically confirmed influenza (>/=4-fold increase in haemagglutination-inhibition titre) occurred among 77 amantadine-treated subjects for whom paired sera were available but there were 13 such cases among the 74 placebo subjects with paired sera. These differences are statistically highly significant. No serious side-effects were recorded.The authors conclude that amantadine was highly effective in preventing overt disease and discuss indications that suggest that it did not interfere with the development of immunity in persons treated during the incubation period.
1969年3月在罗马尼亚布拉索夫爆发由香港病毒引起的流感疫情期间,开展了一项双盲试验,调查金刚烷胺对A2/香港流感的预防效果。该试验共纳入215名受试者;112人每天两次服用100毫克金刚烷胺,持续20天,其余103人服用惰性安慰剂片。在接受金刚烷胺治疗的组中,2人出现临床症状被诊断为流感(其中1例诊断存疑),而安慰剂组有20人(1例存疑)出现此类症状。在有配对血清的77名接受金刚烷胺治疗的受试者中,没有出现临床症状且血清学确诊为流感(血凝抑制效价升高≥4倍)的病例,但在有配对血清的74名安慰剂受试者中有13例此类病例。这些差异具有高度统计学意义。未记录到严重副作用。作者得出结论,金刚烷胺在预防显性疾病方面非常有效,并讨论了表明其在潜伏期治疗的人群中不干扰免疫力发展的迹象。